Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AnaptysBio, Inc.    ANAB

ANAPTYSBIO, INC.

(ANAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Glancy Prongay & Murray LLP :, a Leading Securities Fraud Law Firm, Announces Investigation of AnaptysBio, Inc. (ANAB) on Behalf of Investors

share with twitter share with LinkedIn share with facebook
share via e-mail
03/26/2020 | 05:31pm EDT

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB) investors concerning the Company and its officers’ possible violations of the federal securities laws.

If you suffered a loss on your AnaptysBio investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information here or contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, via email shareholders@glancylaw.com or visit our website at www.glancylaw.com to learn more about your rights.

On March 26, 2018, AnaptysBio revealed data from an interim analysis of a Phase 2a trial for etokimab in adult patients with peanut allergies. Though the Company reported improvement among patients who received a single dose of etokimab compared to patients dosed with a placebo, later that day, an analyst from RBC Capital Markets issued a report that questioned the accuracy of that data.

On this news, the Company’s share price fell $6.31 per share, or over 5%, to close at $107.52 per share on March 27, 2018, thereby injuring investors.

Then on June 21, 2019, an analyst from Credit Suisse issued a report questioning the accuracy of the Company's Phase 2a atopic dermatitis data, concluding that due to lack of critical details provided by the Company as well as the study’s small sample size, "we must consider the possibility that the presence of rescue medications could have influenced the trial's response rates" and "we are now less certain about etokimab's efficacy profile." Thus, Credit Suisse downgraded AnaptysBio stock to neutral from outperform and slashed its price target to $79 from $137.

On this news, the Company’s share price fell $7.78 per share, or over 11%, to close at $59.24 per share on June 21, 2019.

Finally, on November 8, 2019, the Company announced "very disappoint[ing]" data from its ATLAS trial, a Phase 2b multi-dose study which evaluated the efficacy of etokimab in patients with moderate-to-severe atopic dermatitis. Specifically, AnaptysBio disclosed that each of the etokimab dosing arms "failed to meet the primary endpoint of the trial" and revealed that, as a result of this data, it had postponed the initiation of its Phase 2b etokimab clinical trial in asthma.

On this news, the Company’s share price fell $25.98 per share, or over 71%, to close at $10.18 per share on November 8, 2019, thereby injuring investors further.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding AnaptysBio should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM’s lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ANAPTYSBIO, INC.
03/27ANAB ALERT : ROSEN, GLOBAL INVESTOR COUNSEL, Announces Filing of Securities Clas..
PR
03/27GLANCY PRONGAY & MURRAY LLP : Announces the Filing of a Securities Class Action ..
BU
03/27Law Offices of Howard G. Smith Announces the Filing of a Securities Class Act..
BU
03/27SHAREHOLDER ALERT : Robbins LLP Announces AnaptysBio, Inc. (ANAB) Sued for Misle..
BU
03/27THE LAW OFFICES OF FRANK R. CRUZ : Announces Investigation on Behalf of AnaptysB..
BU
03/27ANAB ALERT : Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anapt..
PR
03/27INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
03/26HAGENS BERMAN, NATIONAL TRIAL ATTORN : Securities Fraud Class Action Filed
PR
03/26ANAPTYSBIO ALERT : Bragar Eagel & Squire, P.C. Announces That a Class Action Law..
BU
03/26GLANCY PRONGAY & MURRAY LLP : a Leading Securities Fraud Law Firm, Announces Inv..
BU
More news
Financials (USD)
Sales 2020 21,7 M
EBIT 2020 -78,9 M
Net income 2020 -73,9 M
Finance 2020 278 M
Yield 2020 -
P/E ratio 2020 -5,56x
P/E ratio 2021 -4,64x
EV / Sales2020 4,80x
EV / Sales2021 23,8x
Capitalization 382 M
Chart ANAPTYSBIO, INC.
Duration : Period :
AnaptysBio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANAPTYSBIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 18,00  $
Last Close Price 14,00  $
Spread / Highest target 100%
Spread / Average Target 28,6%
Spread / Lowest Target 0,00%
EPS Revisions
Managers
NameTitle
Hamza Suria President, Chief Executive Officer & Director
James N. Topper Chairman
Eric J. Loumeau Chief Financial Officer & General Counsel
Hollings Chase Renton Lead Independent Director
John P. Schmid Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANAPTYSBIO, INC.-13.85%382
GILEAD SCIENCES12.11%91 719
VERTEX PHARMACEUTICALS-0.78%56 324
REGENERON PHARMACEUTICALS19.72%48 934
WUXI APPTEC CO., LTD.1.28%21 638
GENMAB A/S-9.38%12 982